NeuroSense Therapeutics (NASDAQ:NRSN) Shares Down 19.8%

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN – Get Rating)’s stock price dropped 19.8% on Friday . The stock traded as low as $1.62 and last traded at $1.78. Approximately 2,436,058 shares traded hands during trading, a decline of 63% from the average daily volume of 6,527,257 shares. The stock had previously closed at $2.22.

NeuroSense Therapeutics Trading Down 19.8 %

The firm has a 50-day moving average of $1.51 and a two-hundred day moving average of $1.76.

NeuroSense Therapeutics (NASDAQ:NRSN – Get Rating) last posted its quarterly earnings results on Thursday, December 1st. The company reported ($0.25) earnings per share for the quarter.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Jane Street Group LLC grew its stake in NeuroSense Therapeutics by 77.6% in the second quarter. Jane Street Group LLC now owns 77,249 shares of the company’s stock valued at $261,000 after purchasing an additional 33,751 shares in the last quarter. Vanguard Personalized Indexing Management LLC purchased a new position in NeuroSense Therapeutics in the second quarter valued at about $134,000. Renaissance Technologies LLC purchased a new position in NeuroSense Therapeutics in the third quarter valued at about $97,000. Millennium Management LLC purchased a new position in NeuroSense Therapeutics in the second quarter valued at about $68,000. Finally, Bank of Montreal Can purchased a new position in NeuroSense Therapeutics in the first quarter valued at about $65,000. Hedge funds and other institutional investors own 0.67% of the company’s stock.

NeuroSense Therapeutics Company Profile

(Get Rating)

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. Its lead product is PrimeC, an extended-release oral formulation of a fixed dose combination of ciprofloxacin and celecoxib for the treatment of amyotrophic lateral sclerosis.